ID: ALA2347209

Max Phase: Preclinical

Molecular Formula: C17H16ClFN4O2

Molecular Weight: 362.79

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@@]1(c2cc(NC(=O)c3ccc(Cl)cn3)ccc2F)CCOC(N)=N1

Standard InChI:  InChI=1S/C17H16ClFN4O2/c1-17(6-7-25-16(20)23-17)12-8-11(3-4-13(12)19)22-15(24)14-5-2-10(18)9-21-14/h2-5,8-9H,6-7H2,1H3,(H2,20,23)(H,22,24)/t17-/m0/s1

Standard InChI Key:  HIFMUVLULGJLTJ-KRWDZBQOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 362.79

Molecular Weight (Monoisotopic): 362.0946

AlogP: 3.08

#Rotatable Bonds: 3

Polar Surface Area: 89.60

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.98

CX LogP: 2.81

CX LogD: 2.67

Aromatic Rings: 2

Heavy Atoms: 25

QED Weighted: 0.88

Np Likeness Score: -1.46

References

1. Hilpert H, Guba W, Woltering TJ, Wostl W, Pinard E, Mauser H, Mayweg AV, Rogers-Evans M, Humm R, Krummenacher D, Muser T, Schnider C, Jacobsen H, Ozmen L, Bergadano A, Banner DW, Hochstrasser R, Kuglstatter A, David-Pierson P, Fischer H, Polara A, Narquizian R..  (2013)  β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.,  56  (10): [PMID:23590342] [10.1021/jm400225m]

2. Woltering TJ, Wostl W, Hilpert H, Rogers-Evans M, Pinard E, Mayweg A, Göbel M, Banner DW, Benz J, Travagli M, Pollastrini M, Marconi G, Gabellieri E, Guba W, Mauser H, Andreini M, Jacobsen H, Power E, Narquizian R..  (2013)  BACE1 inhibitors: a head group scan on a series of amides.,  23  (14): [PMID:23735744] [10.1016/j.bmcl.2013.05.003]

3.  (2015)  Oxazine derivatives, 

Source

Source(2):

• Scientific Literature
• BindingDB Database